Clincosm LogoSign in Get a demo

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Sponsor
ModernaTX, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05868382
Collaborator
(none)
270
Enrollment
10
Locations
6
Arms
9.1
Anticipated Duration (Months)
27
Patients Per Site
3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.

Condition or Disease Intervention/Treatment Phase
  • Biological: mRNA-1010
  • Biological: mRNA-1010.4
  • Biological: mRNA-1010.6
 Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
270 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age
Anticipated Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
Sep 15, 2023
Anticipated Study Completion Date :
Feb 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: mRNA-1010 Dose C

Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

Biological: mRNA-1010
Sterile liquid for injection
Experimental: mRNA-1010.4 Dose B

Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.

Biological: mRNA-1010.4
Sterile liquid for injection
Experimental: mRNA-1010.4 Dose C

Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.

Biological: mRNA-1010.4
Sterile liquid for injection
Experimental: mRNA-1010.6 Dose A

Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.

Biological: mRNA-1010.6
Sterile liquid for injection
Experimental: mRNA-1010.6 Dose B

Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.

Biological: mRNA-1010.6
Sterile liquid for injection
Experimental: mRNA-1010.6 Dose C

Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.

Biological: mRNA-1010.6
Sterile liquid for injection

Outcome Measures

Primary Outcome Measures

  1. Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) [Up to Day 7 (7 days after vaccination)]

  2. Number of Participants with Unsolicited Adverse Events (AEs) [Up to Day 29 (28 days after vaccination)]

  3. Number of Participants with Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), Medically Attended Adverse Events (MAAEs), and AEs Leading to Discontinuation [Day 1 through Day 181]

Secondary Outcome Measures

  1. Change from Baseline in Geometric Mean Titer (GMT), as Measured by Hemagglutinin Inhibition (HAI) Assay [Baseline, Day 181]

  2. Change from Baseline in Geometric Mean Fold Rise (GMFR) of Postinjection/Baseline, as Measured by HAI Assay [Baseline, Day 181]

  3. Percentage of Participants with Seroresponse for mRNA-1010, as Measured by HAI Assay [Day 181]

    Seroresponse is defined as an increase of antibody titers and concentrations from predose below the prespecified lower limit of quantification.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 49 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Investigator has assessed that the participant understands and is willing and physically able to comply with protocol mandated follow up, including all procedures.

  • For assigned females at birth and of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.

Exclusion Criteria:

  • Participant has had close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to Day 1.

  • Participant is acutely ill or febrile (temperature ≥38.0℃elcius [100.4°Fahrenheit]) 72 hours prior to or at the Screening visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window.

  • Participant has a history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.

  • Reported history of congenital or acquired immunodeficiency, immunosuppressive condition or immune-mediated disease, asplenia, or recurrent severe infections.

  • Participant has tested positive for influenza by local health authority-approved testing methods within 150 days prior to Day 1.

  • Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of mRNA vaccines or any components of the mRNA-1010 or influenza vaccines, including egg protein.

  • Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to Day 1 (for corticosteroids, ≥10 mg/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal and topical steroids are allowed. Intra-articular and epidural steroid injections are not allowed within 28 days before and/or after study intervention dosing.

  • Participant has received any vaccine authorized or approved by local health agency ≤28 days prior to study intervention dosing (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after study intervention dosing.

  • Participant has received a licensed seasonal influenza vaccine within 5 months (150 days) prior to Day 1.

  • Participant has participated in any investigational seasonal influenza vaccine study within12 months prior to Day 1.

  • Participant is not aware whether they have received an influenza vaccine in the prior 12 months.

  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to Day 1 or plans to donate blood products during the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CenExel RCA Hollywood Florida United States 33024
2 Suncoast Research Group Miami Florida United States 33135
3 Johnson County Clin-Trials Lenexa Kansas United States 66219
4 Rockville Internal Medicine Rockville Maryland United States 20854
5 DM Clinical Research Southfield Michigan United States 48076
6 Meridian Clinical Research Hastings Nebraska United States 68901
7 Meridian Clinical Research Lincoln Nebraska United States 68510
8 United Medical Associates Binghamton New York United States 13905
9 DM Clinical Research Sugar Land Texas United States 77478
10 Texas Center for Drug Development Tomball Texas United States 77375

Sponsors and Collaborators

  • ModernaTX, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ModernaTX, Inc.
ClinicalTrials.gov Identifier:
NCT05868382
Other Study ID Numbers:
  • mRNA-CRID-004
First Posted:
May 22, 2023
Last Update Posted:
May 22, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by ModernaTX, Inc.
mRNA-1010
Influenza Vaccine
Moderna
Additional relevant MeSH terms:
Influenza, Human

Study Results

No Results Posted as of May 22, 2023